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Background: Invasive treatment (coronary angiography and intervention if feasible) of patients with acute coronary
syndrome (ACS) has been shown to lead to better outcomes than medical therapy alone, but the elderly have
been under-represented in many of the studies. In the elderly, medical therapy is common in ACS. Fear of
complications related to the procedure and unclear benefit in older patients are common reasons for invasive
procedures being withheld. Our hypothesis is that invasive treatment of elderly patients with ACS will lead to a
better outcome in terms of survival and quality of life than medical therapy alone, with acceptable risk.
Methods/Design: This multicenter, randomized controlled trial of patients 80 years of age and over has two
parallel treatment arms, a medical group and an invasive group. In Swedish hospitals, 200 patients with non-ST
elevation myocardial infarction or unstable angina will be randomized to medical or invasive treatment strategy.
The primary outcome measure is the combined endpoint major adverse cardiac or cerebrovascular event (MACCE)
within one year. Secondary outcome measures include quality of life, angina, and adverse events such as bleeding.
Assessments will be conducted during hospitalization, at 1 month after allocation, and at 12 months.
Discussion: This study seeks to determine the efficacy and safety of invasive and medical treatment strategies in
the elderly with ACS. The study is currently recruiting.
Trial registration: ClinicalTrials.gov trial identifier: NCT02126202. Registered on 7 January 2014.
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In acute coronary syndrome (ACS), large randomized
studies have shown a survival benefit of invasive treat-
ment strategy over medical therapy [1,2]. Under-
representation in clinical trials and possibly fear of
complications in older patients has led to a suspected
under-utilization of invasive treatment in the elderly
compared to that in younger population groups. How-
ever, a substudy from a large randomized trial [3] showed
that the oldest patients appeared to benefit the most. In
2007, the American Heart Association published a state-
ment [4] in order to highlight the problem. In contrast, a
recent trial [5] failed to confirm survival benefit in elderly
patients with non-ST elevation myocardial infarction* Correspondence: berglind.libungan@vgregion.se
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unless otherwise stated.ACS unless cardiac enzyme levels were substantially
elevated.
Study objectives and hypothesis
This randomized controlled trial (RCT) aims to address
a fundamental question: which treatment strategy in eld-
erly patients with myocardial infarction results in a bet-
ter outcome with acceptable risk? Specifically, which
treatment strategy improves survival and results in less
morbidity and better quality of life? Equally important
are the adverse events associated with each treatment
strategy.
We hypothesize that revascularization in elderly pa-
tients with ACS will lead to gain in terms of outcome
and quality of life compared to medical therapy alone.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Libungan et al. Trials 2014, 15:349 Page 2 of 5
http://www.trialsjournal.com/content/15/1/349Secondly, we hypothesize that adverse events will occur,
but will be within an acceptable range.
Methods/Design
Design of trial
The octogenarians study is an academically sponsored
and principal investigator-initiated study. The study
design adheres to the ‘CONsolidated Standards of
Reporting Trials’ (CONSORT) statement [6].
The study is a phase 4 RCT with two parallel treat-
ment arms: invasive therapy and medical therapy. Inva-
sive therapy will include a coronary angiography and, if
feasible, revascularization with percutaneous coronary
intervention (PCI) or coronary artery bypass grafting
(CABG). Blinding of study participants is not possible
due to the invasive treatment arm, which makes the trial
an open-label trial.
Participants and recruitment
The trial is a multicenter study. Participants will be
recruited from different sites in the southern and south-
western parts of Sweden. The hospitals participating
are Sahlgrenska University Hospital in Gothenburg,
Norra Älvborg Regional Hospital in Trollhättan, Skåne
University Hospital in Lund, and Skaraborg Hospital in
Skövde.
Participants will be identified by the treating physi-
cians at these hospitals. Patients who meet the inclusion
criteria will be approached by a physician who will pro-
vide a brief summary of the study. If the patient is inter-
ested in taking part, he or she will be asked to provide
written informed consent. The inclusion criteria are:
equal or greater than 80 years of age; ACS with ischemic
symptoms (mainly chest pain) lasting over 10 minutes
within the previous 72 hours, and ischemic ST-segment
depression ≥ 1 mm and/or elevated troponin I, troponin
T, or CK-MB; and written informed consent provided
before randomization.
The exclusion criteria are: PCI within 30 days prior to
randomization; suspected ongoing active internal bleed-
ing; ST-segment elevation of ≥ 1 mm in two contiguous
leads on ECG (electrocardiogram) enrollment in another
study that has not completed the follow-up phase; known
allergy to aspirin or P2Y12 antagonists; severe dementia;
expected limited 1-year survival due to another disease
(s); and unwillingness to participate in the trial or ex-
pected problems with compliance. Patients who meet the
inclusion criteria but who are not able to participate for
various reasons will be registered in a trial screening log.
Ethics and procedure
The ethical aspects of this study have been approved by
the Ethical Review Board in Gothenburg (Diarie number157–09). The project will be conducted according to the
World Medical Association Declaration of Helsinki [7].
Randomization
The age of participants (between 80 and 84-years-old
or ≥85-years-old) will be used to determine the sub-
group for random allocation. This stratification is due to
the possibility of unbalanced treatment arms regarding
age. The random assignment to one of the two treat-
ment arms will be conducted independently of the pro-
ject staff by using sequentially numbered and sealed
opaque envelopes. The envelopes will contain the group
allocation on a written insert, based on a predetermined
random computer-generated sequence.
Crossover
Efforts should be made to keep the initial treatment allo-
cation, but a certain crossover rate can be expected. Pa-
tients randomized to the invasive treatment group will
receive medical treatment in case of coronary anatomy
unsuitable for intervention. Patients in the medical treat-
ment group will undergo coronary angiography with
possible revascularization in case of ischemia leading to
refractory chest pain, hemodynamic instability (including
cardiogenic chock), heart failure, or life-threatening car-
diac arrhythmias.
Intervention procedures
Invasive treatment (intervention arm of the RCT): coron-
ary angiography will be performed with the use of 5 to
8 F catheters via the femoral or radial approach at the
operator’s discretion. Revascularization with PCI or
CABG will be performed if feasible and if acceptable to
the patient. For all patients, standard medication (as
mentioned below) will be administered if the patient has
no contraindications. If PCI is performed, the patients
will be treated with heparin or bivalirudin according to
local guidelines and at the operator's discretion. Medical
treatment (control arm of the RCT): patients randomized
to medical treatment will receive optimized medical
treatment and will not undergo a coronary angiography.
Trial medication
The following medication is recommended but not
mandatory in both treatment arms.
Aspirin will be administered to all patients on a daily
basis in a maintenance dose of between 75 and 160 mg.
If the patient is previously untreated with aspirin, a load-
ing dose of between 160 and 320 mg will be given.
Other antiplatelet medications include clopidogrel
(with a loading dose of between 300 and 600 mg) or
ticagrelor (loading dose of 180 mg) will be administered
as soon as possible, and always before the coronary angi-
ography, in patients randomized to invasive treatment.
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started as soon as possible. Beta-blockers are often in-
cluded as an anti-ischemic treatment in the absence of
contraindications. Long-term treatment is recommended
in the case of reduced left ventricular function. Nitrogly-
cerin (intravenous, oral, sublingual or buccal) is recom-
mended for symptom relief if necessary. ACE inhibitors
are indicated long-term in all patients with heart failure
(left ventricular ejection fraction ≤40%) and in patients
with diabetes mellitus or hypertension.
Definitions
Blood samples for hemoglobin will be obtained at base-
line, and if there is suspicion of bleeding. Blood samples
for platelet count will be obtained at baseline and if
there is suspicion of bleeding. Blood samples for potas-
sium, sodium, and creatinine will be obtained at base-
line. Blood samples for CK-MB (creatine kinase-MB)
and/or Troponin Tor Troponin I will be obtained at
baseline, and if there are symptoms of myocardial ische-
mia. All-cause mortality will be analyzed for this study.
For the purposes of this study ST-elevation myocardial
infarction (STEMI) will be defined as chest pain lasting
more than 10 minutes in combination with ST-segment
elevation (more than 2 mm in two anterior leads, or
more than 1 mm in two inferior leads), or a newly devel-
oped left bundle branch block and elevated cardiac
enzymes/biochemical markers, or a new Q-wave in two
continuous leads on ECG. Non-ST-elevation myocardial
infarction (NSTEMI) will be defined as chest pain lasting
more than 10 minutes in combination with elevated car-
diac troponin levels. Peri- and post-myocardial infarction
will be defined as a myocardial infarction developing
within 24 hours of PCI. This includes STEMI and
NSTEMI with elevated biochemical markers more than
three times normal level unit. A recurrent intervention
is considered to be all unplanned revascularizations after
the index procedure (CABG or PCI). All non-scheduled
hospitalizations due to chest pain, arrhythmias not expe-
rienced previously, or congestive heart failure not expe-
rienced previously will be considered to be recurrent
hospitalization for cardiac reasons. Stroke will be defined
as all ischemic attacks resulting in neurological disor-
ders, including transitory ischemic attack (TIA).
Outcome and safety measurements
There are several secondary outcome measures for this
trial. The definitions of some of the outcome measures
are. Firstly, the grade of angina pectoris as determined
by the patient’s perception of angina pectoris according
to the Seattle Angina Questionnaire (SAQ) [8]. This
assessment will be optional for the patient. Secondly, the
patient’s perception of quality of life according to SF-36
[9]. This assessment will also be optional for the patient.Thirdly, the physician’s perception of frailty at enrollment,
according to the Canadian Study of Health and Aging
(CSHA) Clinical Frailty Scale [10]. Fourthly, major bleed-
ing, defined as either intracranial bleeding, a decrease in
hemoglobin level of more than 50 g/L, or bleeding requir-
ing surgery. Fifthly, minor bleeding, defined as a decrease
in hemoglobin level of more than 30 g/L (but less than
50 g/L), spontaneous gross hematuria, hematemesis,
hematoma, or pseudoaneurysm requiring treatment
(other than surgery). A timeline of the interventions and
measurements is shown in Table 1.
Reporting of adverse events
According to Swedish legislation, the investigator is re-
sponsible for reporting of safety information to local au-
thorities. An adverse event (AE) is any unfavorable sign
or symptom associated with the study agents or the
coronary intervention. A serious adverse event (SAE) is
defined as any AE occurring that results in: death, a life-
threatening event, the prolongation of existing hospi-
talization or new unplanned hospitalization, persistent
or significant disability, or intracranial hemorrhage.
Outcome
Primary outcome
The primary outcome measure is the combined end-
point of a major adverse cardiac or cerebrovascular
event (MACCE) within 1 year. Assessments will be con-
ducted during hospitalization, discharge, after 30 days,
and after 1 year, as shown in Table 1.
Secondary outcome
Secondary outcome measures include: any MACCE
within 1 month, death at 1 year, any myocardial infarc-
tion at 1 year, death or myocardial infarction at 1 year,
major bleeding at 30 days, and minor bleeding at 30 days.
Sample size
According to previous trials, such as the TACTICS-
TIMI 18 elderly substudy [3], we expect a MACCE rate
of 40% within one year of allocation with the conserva-
tive strategy, and that this could be reduced to 20% with
an invasive strategy. With 80% power and an α level
of <0.05, this trial will require 82 individuals in each
group. Due to possible dropout, 200 patients will be
included in the trial; 100 in each treatment arm. No
interim analysis is planned.
Data and statistical analysis
Data will be entered into each patient’s case report form
(CRF). The principal investigator is the data custodian.
Data will be screened and, if necessary, cleaned (the
process of detecting and correcting corrupt or inaccur-
ate records from a record set, table, or database) in
Table 1 Schedule of enrollment, interventions, assessments, and outcome/safety measures for the octogenarian study
STUDY PERIOD
Enrollment allocation Post-allocation Close-out








Invasive treatment strategy X
Assessments:
Echocardiography and frailty score X
QoL and angina questionnaire X X
Adverse events X X X X





Safety measure: bleeding X X X X
*Medical treatment will be given to all study participants regardless of treatment allocation, provided that there are no contraindications.
**If symptoms of ischemia: ECG, CK-MB, and cardiac troponins. If symptoms of bleeding: hemoglobin and platelet count.
***Combined endpoint: MACCE: major adverse cardiac or cerebral event.
§Primary endpoint of the study.
QoL: Quality of life, ECG: Electrocardiogram.
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lysis will be managed according to the intention-to-treat
principle.Discussion
This study seeks to determine the efficacy and safety of
invasive and medical treatment strategies in elderly pa-
tients with ACS. In doing so, the study will advance our
understanding of therapy choice in elderly patients with
ACS. The different treatment strategies have the poten-
tial to reduce angina pectoris and complications, and
improve quality of life and survival.Trial status
Recruitment to the study commenced in October 2009
and is still continuing to recruit patients. The recruit-
ment of all patients will hopefully be finished in year
2015.
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